News Releases

News and information from The Leukemia & Lymphoma Society

LLS Response to Approval of Right to Try Legislation

Rye, Brook, NY (May 23, 2018)  – The House of Representatives yesterday voted 250-169 in favor of the Right to Try Act, which the Senate passed in August 2017. The bill will now be sent to President Trump, who is expected to sign it. The Right to Try Act fails to meet all of The Leukemia & Lymphoma Society’s (LLS) principles regarding access to investigational therapies, which are outlined below....

LLS Applauds Congressional Approval of the Childhood Cancer STAR Act

Washington, D.C. (May 23, 2018) – The Leukemia & Lymphoma Society (LLS) commends the U.S. House of Representatives for unanimously approving the Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act yesterday. Led by Representative Michael McCaul (R-Texas), Representative Jackie Speier (D-Calif.), Representative Mike Kelly (R-Pa.) and Representative G. K. Butterfield (D-N.C.) in the U.S. Hou...

LLS Statement on Trump Administration’s Blueprint on Drug Prices

Rye Brook, NY (May 14, 2018) – President Trump gave a speech on Friday May 11, 2018 outlining his administration’s proposal to bring down the cost of drugs. Following is a statement from The Leukemia & Lymphoma Society’s President and CEO Louis J. DeGennaro: The Leukemia and Lymphoma Society (LLS) is pleased that the Trump Administration has publicly committed to making prescription drugs more afforda...

LLS Unveils “Beating Cancer Is In Our Blood” Brand Platform

View multimedia release here. Rye Brook, N.Y. (May 7, 2018) – The Leukemia & Lymphoma Society (LLS), the largest nonprofit dedicated to fighting blood cancers, today unveiled a new brand platform showcasing its work in the fight to cure cancers. “Beating Cancer Is In Our Blood” highlights LLS’s resolve to end blood cancers, the third leading cause of cancer deaths in the U.S., and sh...

More Progress on LLS-Supported CAR T-cell Immunotherapy

Rye Brook, N.Y. (May 2, 2018) – The latest approval of a game-changing personalized cancer therapy on Tuesday is further proof of the promise of  immunotherapy, an approach that The Leukemia & Lymphoma Society (LLS) supported early on and which holds great promise for blood cancer patients, as well as for patients with other types of cancers.   The U.S. Food and Drug Administration (FDA) granted ti...

Leukemia Patient’s Legacy Helps Drive Innovative Cancer Clinical Trial

Rye Brook, NY (March 21, 2018) - Turning sorrow into action, The Harry T. Mangurian Jr. Foundation, whose namesake died from acute myeloid leukemia (AML), continues to fuel The Leukemia & Lymphoma Society’s (LLS) ambitious attack on this deadly blood cancer.  Specifically, with the Foundation’s support, LLS is leading a paradigm shift to treating cancers with a precision medicine approach – the right d...

When Competition and Philanthropy Go Hand-in-Hand

Rye Brook, NY - March 15, 2018 – One of the greatest competitors of all time, Michael Jordan, once said, “Talent wins games, but teamwork and intelligence win championships.” Today, The Leukemia & Lymphoma Society® (LLS) officially kicks off the 29th annual competitive fundraising campaign, Man & Woman of the Year®. In 80 communities across the country, a select group of individuals and their cam...

The Time is Now for More Women in Science

View multimedia release here.  Rye Brook, N.Y. (March 13, 2018) – As breakthroughs in cancer treatments are occurring at an ever increasing rate, The Leukemia & Lymphoma Society (LLS) is shining a spotlight on the women in science who are helping to lead these advances.  Through its significant investment in cancer research – more than $1.2 billion since its founding nearly 70 years ago – LL...

Pages

Media Contact

Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday: